バイオ医薬品受託製造の市場規模・シェア・成長分析 (サービス別、種類別、運営規模別、原料別、分子の種類別、地域別)：産業予測 (2025～2032年)

世界のバイオ医薬品受託製造の市場規模は2023年に165億米ドルと評価され、2024年の178億5,000万米ドルから2032年には335億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは8.2％で成長する見通しです。

世界のバイオ医薬品受託製造市場は、新薬開発に必要な投資の削減、先端技術へのアクセス強化、革新的製品の迅速な市場参入などを背景に、大きく成長する見通しです。特に、サーモフィッシャーサイエンティフィックが最近1億8,000万米ドルを投じてプレーンビルに新たな製造施設を建設したことは、この動向を象徴しており、消費者需要の急増に対応するための生産能力の増強が可能になります。さらに、バイオプロセスにおける急速な技術進歩が、高コストやバッチ切り替えの問題といった従来の製造課題を軽減し、世界中の受託サービス業者の能力を高めています。さらに、バクスター・インターナショナルが2021年にCOVID-19ワクチン製造のためにバクスター・バイオファーマ・ソリューションズと提携したことに示されるように、主要起業間の戦略的合併、買収、合弁事業がこれらのサービスに対する需要を促進しています。

目次

イントロダクション

• 分析目的
• 市場範囲
• 定義

分析手法

• 情報調達
• 二次・一次データの手法
• 市場規模予測
• 市場の想定と制約

エグゼクティブサマリー

• 市場の概要と展望
• 需給動向の分析
• セグメント別の機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

市場の主な考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場魅力度指数 (2024年)
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術分析
• 規制分析
• 特許分析
• ケーススタディ
• FDA公認のバイオ医薬品CMOセンター

世界のバイオ医薬品受託製造の市場規模・CAGR：サービス別 (2025～2032年)

• 市場概要
• 製造業
• 配合・充填・仕上げ
• 包装・ラベル
• その他のサービス

世界のバイオ医薬品受託製造の市場規模・CAGR：種類別 (2025～2032年)

• 市場概要
• 生物製剤の原薬製造
• 生物製剤の製品製造

世界のバイオ医薬品受託製造の市場規模・CAGR：運営規模別 (2025～2032年)

• 市場概要
• 商業運営
• 臨床運営

世界のバイオ医薬品受託製造の市場規模・CAGR：原料別 (2025～2032年)

• 市場概要
• 哺乳細胞発現系
• 非哺乳細胞発現系

世界のバイオ医薬品受託製造の市場規模・CAGR：分子の種類別 (2025～2032年)

• 市場概要
• モノクローナル抗体
• 細胞・遺伝子治療
• 抗体薬物複合体
• ワクチン
• 治療用ペプチドとタンパク質
• その他の分子タイプ

世界のバイオ医薬品受託製造の市場規模・CAGR：治療領域別 (2025～2032年)

• 市場概要
• 腫瘍学
• 自己免疫疾患
• 代謝性疾患
• 心血管疾患
• 神経学
• 感染症
• その他の治療領域

世界のバイオ医薬品受託製造の市場規模・CAGR (2025～2032年)

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング (2024年)
• 主要企業が採用した戦略
• 市場の近年の動向
• 主要企業の市場シェア (2024年)
• 主要企業のプロファイル
  • 企業概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較 (2022～2024年)

主要企業のプロファイル

• Lonza (スイス)
• Thermo Fisher Scientific Inc. (米国)
• WuXi Biologics (中国)
• Catalent, Inc. (米国)
• Samsung Biologics (韓国)
• Boehringer Ingelheim International GmbH (ドイツ)
• Fujifilm Holdings Corporation (日本)
• AbbVie Inc. (米国)
• Eurofins Scientific（ルクセンブルク）
• GenScript Biotech Corporation (中国)
• AGC Inc. (日本)
• Merck
• KGaA (ドイツ)
• JSR Corporation (日本)
• Stelis（India）
• Recipharm AB (スウェーデン)
• Emergent (米国)
• Shanghai Fosun Pharmaceutical Co., Ltd. (中国)
• Lotte Biologics (韓国)
• Hepalink Group (中国)
• Curia Global, Inc. (米国)

結論と推奨事項

Global Biopharmaceuticals Contract Manufacturing Market size was valued at USD 16.5 billion in 2023 and is poised to grow from USD 17.85 billion in 2024 to USD 33.54 billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

The global biopharmaceuticals contract manufacturing market is poised for significant growth, driven by reduced investment needs for new drug development, enhanced access to advanced technologies, and expedited market entry for innovative products. Notably, Thermo Fisher Scientific's recent USD 180 million investment in a new manufacturing facility in Plainville exemplifies this trend, enabling increased production capacity to meet surging consumer demand. Additionally, rapid technological advancements in bioprocessing are alleviating traditional manufacturing challenges, such as high costs and batch changeover issues, boosting the capabilities of contract service providers worldwide. Furthermore, strategic mergers, acquisitions, and joint ventures among key market players are fueling demand for these services, as illustrated by Baxter International's collaboration with Baxter BioPharma Solutions for COVID-19 vaccine production in 2021.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceuticals Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceuticals Contract Manufacturing Market Segmental Analysis

Global Biopharmaceuticals Contract Manufacturing Market is segmented by Service, Type, Scale Of Operation, Source, Molecule Type,TherapeuticArea and region. Based on Service, the market is segmented into Manufacturing, Formulation & Fill-Finish, Packaging & Labeling and Other Services. Based on Type, the market is segmented into Biologic Drug Substance Manufacturing and Biologic Drug Product Manufacturing. Based on Scale Of Operation, the market is segmented into Commercial Operations and Clinical Operations. Based on Source, the market is segmented into Mammalian Expression Systems and Non-Mammalian Expression Systems. Based on Molecule Type, the market is segmented into Monoclonal Antibodies, Cell & Gene Therapies, Antibody-Drug Conjugates, Vaccines, Therapeutic Peptides & Proteins and Other Molecule Types. Based on Therapeutic Area, the market is segmented into Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Neurology, Infectious Diseases and Other Therapeutic Areas. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biopharmaceuticals Contract Manufacturing Market

The global biopharmaceuticals contract manufacturing market is primarily driven by the surging demand for biological therapies, which is influenced by several key factors. Notably, the continual rise in the demand for generics, coupled with heightened research and development efforts and investments in cutting-edge technologies, is expected to propel market growth during the forecast period. Additionally, the expansion of the nuclear medicine sector and a greater focus on specialty medicines are anticipated to further stimulate market progression. These elements collectively contribute to a promising landscape for the biopharmaceuticals contract manufacturing market in the years ahead.

Restraints in the Global Biopharmaceuticals Contract Manufacturing Market

The global biopharmaceuticals contract manufacturing market is facing several restraints that hinder its growth during the forecast period. Key challenges include labeling and packaging complications, along with sterilization issues that complicate the manufacturing process. Furthermore, a general lack of consumer trust combined with insufficient knowledge regarding the manufacturing processes may further restrict market expansion in the upcoming years. These various associated problems are critical factors that stakeholders need to address in order to facilitate smoother operations and enhance market performance in the highly competitive biopharmaceuticals landscape.

Market Trends of the Global Biopharmaceuticals Contract Manufacturing Market

The Global Biopharmaceuticals Contract Manufacturing market is witnessing a notable trend driven by technological advancements, particularly the integration of artificial intelligence (AI). In recent years, the surge in scientific exploration aimed at addressing critical health challenges has propelled market expansion. AI's burgeoning role in analyzing patient symptoms and facilitating real-time data tracking for disease patterns is revolutionizing manufacturing processes. This technological synergy not only enhances efficiency but also fosters innovation in drug development, leading to improved therapeutic solutions. As a result, stakeholders can anticipate robust growth opportunities in the biopharmaceutical contract manufacturing sector in the foreseeable future.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies
• FDA Approved Biopharmaceuticals CMOs Centers

Global Biopharmaceuticals Contract Manufacturing Market Size by Service & CAGR (2025-2032)

• Market Overview
• Manufacturing
• Formulation & Fill-Finish
• Packaging & Labeling
• Other Services

Global Biopharmaceuticals Contract Manufacturing Market Size by Type & CAGR (2025-2032)

• Market Overview
• Biologic Drug Substance Manufacturing
• Biologic Drug Product Manufacturing

Global Biopharmaceuticals Contract Manufacturing Market Size by Scale Of Operation & CAGR (2025-2032)

• Market Overview
• Commercial Operations
• Clinical Operations

Global Biopharmaceuticals Contract Manufacturing Market Size by Source & CAGR (2025-2032)

• Market Overview
• Mammalian Expression Systems
• Non-Mammalian Expression Systems

Global Biopharmaceuticals Contract Manufacturing Market Size by Molecule Type & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Cell & Gene Therapies
• Antibody-Drug Conjugates
• Vaccines
• Therapeutic Peptides & Proteins
• Other Molecule Types

Global Biopharmaceuticals Contract Manufacturing Market Size by Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Oncology
• Autoimmune Diseases
• Metabolic Diseases
• Cardiovascular Diseases
• Neurology
• Infectious Diseases
• Other Therapeutic Areas

Global Biopharmaceuticals Contract Manufacturing Market Size & CAGR (2025-2032)

• North America (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • US
  • Canada
• Europe (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JSR Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stelis (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Fosun Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lotte Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepalink Group (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations